These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 11126389)

  • 41. Brain-derived neurotrophic factor mechanisms and function in adult synaptic plasticity: new insights and implications for therapy.
    Kuipers SD; Bramham CR
    Curr Opin Drug Discov Devel; 2006 Sep; 9(5):580-6. PubMed ID: 17002218
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Lithium and neuropsychiatric therapeutics: neuroplasticity via glycogen synthase kinase-3beta, beta-catenin, and neurotrophin cascades.
    Wada A
    J Pharmacol Sci; 2009 May; 110(1):14-28. PubMed ID: 19423950
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Neuroplasticity-related mechanisms underlying the antidepressant-like effects of traditional herbal medicines.
    Hirshler Y; Doron R
    Eur Neuropsychopharmacol; 2017 Oct; 27(10):945-958. PubMed ID: 28807619
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Neurotrophins as mediators of drug effects on mood, addiction, and neuroprotection.
    Castrén E
    Mol Neurobiol; 2004 Jun; 29(3):289-302. PubMed ID: 15181240
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Mechanisms of action in the prevention of recurrent mood disorders.
    Baumann B; Krell D; Dobrowolny H; Bielau H
    Pharmacopsychiatry; 2004 Nov; 37 Suppl 2():S157-64. PubMed ID: 15546069
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Emerging experimental therapeutics for bipolar disorder: clues from the molecular pathophysiology.
    Quiroz JA; Singh J; Gould TD; Denicoff KD; Zarate CA; Manji HK
    Mol Psychiatry; 2004 Aug; 9(8):756-76. PubMed ID: 15136795
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Lithium at 50: have the neuroprotective effects of this unique cation been overlooked?
    Manji HK; Moore GJ; Chen G
    Biol Psychiatry; 1999 Oct; 46(7):929-40. PubMed ID: 10509176
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Role of glial cell line-derived neurotrophic factor in the pathogenesis and treatment of mood disorders.
    Tsybko AS; Ilchibaeva TV; Popova NK
    Rev Neurosci; 2017 Apr; 28(3):219-233. PubMed ID: 28099138
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cellular plasticity cascades: targets for the development of novel therapeutics for bipolar disorder.
    Zarate CA; Singh J; Manji HK
    Biol Psychiatry; 2006 Jun; 59(11):1006-20. PubMed ID: 16487491
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Multiple levels of impaired neural plasticity and cellular resilience in bipolar disorder: developing treatments using an integrated translational approach.
    Machado-Vieira R; Soeiro-De-Souza MG; Richards EM; Teixeira AL; Zarate CA
    World J Biol Psychiatry; 2014 Feb; 15(2):84-95. PubMed ID: 23998912
    [TBL] [Abstract][Full Text] [Related]  

  • 51. New understanding of mechanisms of action of bipolar medications.
    Sanacora G
    J Clin Psychiatry; 2008; 69 Suppl 5():22-7. PubMed ID: 19265637
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Neurotrophins and hippocampal synaptic transmission and plasticity.
    Lu B; Chow A
    J Neurosci Res; 1999 Oct; 58(1):76-87. PubMed ID: 10491573
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Sleep Markers in Psychiatry: Do Insomnia and Disturbed Sleep Play as Markers of Disrupted Neuroplasticity in Mood Disorders? A Proposed Model.
    Palagini L; Geoffroy PA; Riemann D
    Curr Med Chem; 2022; 29(35):5595-5605. PubMed ID: 34906053
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Life stress, genes, and depression: multiple pathways lead to increased risk and new opportunities for intervention.
    Charney DS; Manji HK
    Sci STKE; 2004 Mar; 2004(225):re5. PubMed ID: 15039492
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Neurotrophic signaling cascades in the pathophysiology and treatment of bipolar disorder.
    Shaltiel G; Chen G; Manji HK
    Curr Opin Pharmacol; 2007 Feb; 7(1):22-6. PubMed ID: 17055337
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Post-receptor signaling pathways in the pathophysiology and treatment of mood disorders.
    Manji HK; Chen G
    Curr Psychiatry Rep; 2000 Dec; 2(6):479-89. PubMed ID: 11122999
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Neuroplasticity as a target for the pharmacotherapy of anxiety disorders, mood disorders, and schizophrenia.
    Krystal JH; Tolin DF; Sanacora G; Castner SA; Williams GV; Aikins DE; Hoffman RE; D'Souza DC
    Drug Discov Today; 2009 Jul; 14(13-14):690-7. PubMed ID: 19460458
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Molecular targets of lithium action.
    Corbella B; Vieta E
    Acta Neuropsychiatr; 2003 Dec; 15(6):316-40. PubMed ID: 26983769
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Targeting signal transduction pathways in the treatment of mood disorders: recent insights into the relevance of the Wnt pathway.
    Gould TD; Dow ER; O'Donnell KC; Chen G; Manji HK
    CNS Neurol Disord Drug Targets; 2007 Jun; 6(3):193-204. PubMed ID: 17511616
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Glia as targets for antidepressants: an involvement in glial cell line-derived neurotrophic factor].
    Hisaoka K; Takebayashi M
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2007 Nov; 27(5-6):173-9. PubMed ID: 18154038
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.